Clinical Trials Arena February 28, 2023
Bioethicist Alison Bateman-House, PhD, discusses the ethics of developing rare disease treatments with equity and access in mind.
As breakthroughs in gene therapy and personalized medicine hit the market, the rare disease community is hopeful for new treatment options to target enormous unmet needs. At the same time, there are swirling questions over the ethics of steep drug prices and the challenges of ensuring patient access to treatments, both in and outside of the clinical trial setting.
Alison Bateman-House, PhD, is a bioethicist at New York University focused on the ethics of rare disease drug development. Her work explores on the challenges of testing and regulating experimental treatments for ultra-rare diseases, including gene therapies and antisense...
Today's Sponsors
Today's Sponsor